Moderna Plans to Use Massachusetts Facility as Global Supply Hub for Cancer Vaccine
Moderna (MRNA) has announced plans to designate its biomanufacturing facility in Massachusetts as the primary global supply site for its experimental cancer vaccine. Developed in collaboration with Merck (MRK), the vaccine is a key component of the company's long-term growth strategy. The facility is scheduled to begin shipping clinical study materials starting in September 2025. This strategic move aims to centralize production capabilities to meet anticipated global demand as the therapeutic moves through its development pipeline.
Topics: biomanufacturing cancer vaccine supply chain expansion